Advertisement


Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?

2022 ASCO Annual Meeting

Advertisement

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial lung disease; tumor targeting and payload release; drug resistance; and the urgent need to understand ADCs’ mechanisms of action to better sequence and combine drugs.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Ann H. Partridge: Veronique, it's been a pretty exciting ASCO to be a breast cancer doctor and researcher. Tell me about these new drugs, the antibody conjugates that are making such a splash. Véronique Diéras: Yes. And in fact, it took more than a century to have this targeted chemotherapy in order to improve the therapeutic index of cytotoxic chemotherapy. We were using TDM-1 for many years, but the third generation of ADC have some particular and mainly the bystander effect what we call. So there is a release of the cytotoxic, the payload of the antibody in the micro environment, leading to activity in tumor cells that might not express the target of the ADC. So the bystander effect may increase the efficacy of the ADC, but also perhaps the toxicity. Ann H. Partridge: So it allows for that tumor heterogeneity that we're learning so much about to be targeted? Véronique Diéras: Yes, exactly. Tumor heterogeneity and moreover targeting tumor cells with low expression. We know, for instance, with the anti-ER therapy, it was active only in case of early to free expression, like for TDM-1 trastuzumab. And then with this new ADC and the bystander effect, there may be some activity on HE. Ann H. Partridge: R2 low expression, breast cancer. Ann H. Partridge: Yeah, and what do you mean by activity? What have we seen both in your work and what we saw here at ASCA? Véronique Diéras: Trastuzumab deruxtecan was very active in HER positive breast, metastatic breast cancer, according to the [inaudible] breast of free. But at this ASCO, we heard about the activity in HER2 low breast cancer. We have already refuted data from the early clinical trials, but we have the release of destiny breast or four comparing Trastuzumab deruxtecan versus chemotherapy choice of the physician. In every treated patient mainly ER positive too low, but some were negative. And clearly the results were impressive with a superiority, not only in probation free survival, but in response rate and interval survival. That means a lot for our patient because I think there will be a major impact for two mobile in our clinical practice. Ann H. Partridge: Right. And it worked in all subsets. Right? Véronique Diéras: Exactly. Ann H. Partridge: All subtypes. Yeah. If they express some HER2, right? Véronique Diéras: Yes. HER2 low, even if it's ER negative. So what we may call triple negative by the definition of today, we may have some activity too. Ann H. Partridge: That's right. About 30% express some HER2 correct? Véronique Diéras: Yes. Ann H. Partridge: Something like that. And what about the tolerability of these drugs? What are we learning? Véronique Diéras: There's no new safety signals from what we know from destiny breast free, it was an update of the safety during this meeting too. But perhaps we have to be cautious about interstitial lung disease, ILD, but in fact the incidence on the severity of ILD decrease with the implementation of guidelines and perhaps more over treating less pretreated population. Ann H. Partridge: So now we have a number of monoclonal antibody, conjugate drugs, where do we go from here? Where do we need to go research wise and what can we do on Monday in the clinic? Véronique Diéras: So on Monday in the clinic, we may use precision risk account, but in fact, we have many ADC with different target from HER2 low from HER3 and from [inaudible]. Véronique Diéras: And we have activity, I think HER3, we have as a preliminary development, but it's very exciting data. We have from the phase one and two study, but for tomorrow, what we need to know the best, we will address this ADC on the sequencing, the choice of the ADC for each patient. So today we say, considering the result we have with Trastuzumab [inaudible] HER2 low, ER positive, I will say the best choice will be Trastuzumab deruxtecan because we have an impact on world survival, but we may have activity with Trop2 ADC. So we have for the next future to evaluate the sequencing of this ADC, to evaluate the mechanism of resistance, because it'll have an important value to set the sequence. And also perhaps combination because we know from cyto toxic chemotherapy. When we combine with other drug immune checkpoint inhibitor, PAP inhibitor, sometimes we may have increase of activity. So we have a lot. I think it's the beginning of the story of it, in fact. Ann H. Partridge: So the beginning, and wouldn't it be nice if we could have a cocktail and then move it into the earlier stage setting and effect more cures? Véronique Diéras: Yes. Ann H. Partridge: That's what we want to see ultimately. Véronique Diéras: Yes, exactly. I was thinking of that, looking to the result of this of study of four. When I see the response rate in every pre-treated population. What may be the impact for instance, in the new adjuvant setting for ER positive, HER2 low, because we know usually the PCR is very low in ER positive diseases. So perhaps we have to evaluate Trastuzumab in the adjuvant setting to increase the PCR to have an impact on the cure of the patient. Ann H. Partridge: All right. I heard it here. I think that's the future. Thank you so much Veronique for joining me. Véronique Diéras: Thank you.

Related Videos

Myelodysplastic Syndromes

Ruben A. Mesa, MD, on Myelofibrosis: Phase III Results on Momelotinib vs Danazol

Ruben A. Mesa, MD, of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses new findings from the MOMENTUM study. This trial showed that in symptomatic and anemic patients with myelofibrosis, momelotinib was superior to danazol for symptom and spleen responses, as well as transfusion requirements (Abstract 7002).

Breast Cancer

Robert Hugh Jones, MD, PhD, on Breast Cancer: Updated Overall Survival Data on Fulvestrant Plus Capivasertib

Robert Hugh Jones, MD, PhD, of Cardiff University and Velindre Hospital, discusses results from an updated analysis of the FAKTION trial, which showed improved overall survival with fulvestrant plus capivasertib in women with metastatic estrogen receptor–positive breast cancer whose disease had relapsed or progressed on an aromatase inhibitor. The benefit may be predominantly in patients with PIK3CA/AKT1/PTEN pathway–altered tumors, a topic researchers continue to study in the phase III CAPItello-291 trial (Abstract 1005).

 

Bladder Cancer

Karim Chamie, MD, on Bladder Cancer: Final Results on N-803 and Bacillus Calmette-Guérin

Karim Chamie, MD, of the University of California, Los Angeles, discusses final clinical results on combining the superagonist N-803 with bacillus Calmette-Guérin (BCG) in patients whose carcinoma in situ and high-grade non–muscle-invasive bladder cancers are unresponsive to BCG alone. Of note, cystectomy was avoided in more than 90% of patients with 2 years of follow-up (Abstract 4508).

Breast Cancer

Nancy Davidson, MD: In It for the Long Haul: Outcomes in Hormone Receptor–Positive Breast Cancer

Nancy Davidson, MD, of the Fred Hutchinson Cancer Research Center, reviews results from four abstracts about the importance of long-term follow-up in studies of adjuvant endocrine therapy for hormone receptor–positive breast cancer. Because the natural history of hormone receptor–positive breast cancer is long, an effort is underway to improve selection of patients by clinical parameters or biomarkers, refine the endocrine therapy background, and administer more effective combinations of endocrine therapy with other agents.

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Michael S. Hofman, MBBS, on Prostate Cancer: New Data on Lutetium-177–PSMA-617 (LuPSMA) vs Cabazitaxel

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel treatment. The findings suggest that LuPSMA is a suitable option for this population, with fewer adverse events, higher response rates, improved patient-reported outcomes, and similar overall survival compared with cabazitaxel (Abstract 5000).

Advertisement

Advertisement




Advertisement